Found 15 clinical trials
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC) patients with favorable response to induction chemotheray(IC), determining whether radiotherapy combined with nimotuzumab was non-inferior to CCRT and may provide new evidence for individualized comprehensive treatment of …
- 0 views
- 16 Feb, 2024
- 1 location
Investigation of Genomic Alteration in Patients With Luminal A or Luminal B Subtypes
This is a translational study in patients with operated early breast cancer of Luminal A or Luminal B sub types.The Hellenic Cooperative Oncology Group (HeCOG) has designed an observational biomarker-driven study in patients with Luminal A or Luminal B breast cancer, with the aim to collect valuable biological material from …
- 0 views
- 16 Feb, 2024
- 1 location
Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients (EEBC)
The elderly patients over 65 years old with breast cancer have concomitant diseases, poor tolerance to conventional treatment, and the specific prognosis of breast cancer is relatively good. Previous studies on breast cancer have almost excluded elderly breast cancer patients, and conventional treatment schemes cannot meet the clinical diagnosis and …
- 0 views
- 16 Jun, 2023
- 1 location
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e. PFS2-PFS1 = >3 months).
- 0 views
- 16 Feb, 2024
- 1 location
Real-life Pan-HER-blockade With Neratinib
So far, there is no data available on treatment of patients with early-stage hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer, who completed adjuvant trastuzumab-based therapy less than one year ago, in the clinical routine setting.
- 0 views
- 05 Aug, 2020
- 1
- 2